All News
Predictors and Outcomes in Systemic Sclerosis
d
EurekAlert!
The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will fulfil the 2013 ACR/EULAR SSc criteria within 5 years.
Read Article
Expanding the IL-17 Therapeutic Landscape
IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. Is there a need for more medications within the same therapeutic class?
Read Article
Safety of Recombinant Zoster Vaccine in Rheumatic Patients
d
EurekAlert!
New work presented at the 2025 annual EULAR congress in Barcelona focuses on the recombinant zoster vaccine (RZV), which contains recombinant glycoprotein E – the major target of CD4+T-cells.
Read Article
Social Determinants of Health in SLE
d
EurekAlert!
Social determinants of health (SDH), such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases.
Read Article
#Psoriatic_Arthritis
#Preclinical #Early
❓️ Does joint swelling occur in the same anatomical locations affected in the subclinical phase?
🅰️ Yes, in 68%
🅰️ Especially if positive ultrasound
#EULAR2025
@RheumNow
OP0179 by Ivan Giivannini et al. https://t.co/rKfreQyJeG
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2025 Abstr#POS0321 In addition to complete renal response attainment as you already know, exploratory analysis from REGENCY showed Obinutuzumab+SOC reduced #lupus nephritis flare and unfavourable kidney outcomes vs PBO+SOC. Longterm kidney survival protection @RheumNow https://t.co/vRFb94TXaQ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Rheumatoid vasculitis: what to look for and how to find it
#EULAR2025 @AshimaMakol @RheumNow https://t.co/ZCUXgOr1dH
David Liew drdavidliew ( View Tweet)
Acute Dactylitis in #Psoriatic_Arthritis
🔹️1216 patients Canada 🇨🇦
🔹️52% had at least one episode of acute dactylitis in a median 12 years
🔹️Positive association with HLA-B27 and HLA-B27/C02
🔹️No association with HLA-B51
#EULAR2025
@RheumNow
OP0180 by Kharouf et al. https://t.co/oNNMBcvVb4
Nelly ZIADE 🍀 Nellziade ( View Tweet)
How to treat rheumatoid vasculitis
#EULAR2025 @AshimaMakol @RheumNow https://t.co/A8oqPd6bJx
David Liew drdavidliew ( View Tweet)
#EULAR2025 Abstr#OP0324 Cohort study of #lupus nephritis in Greece showed Earlier GC Discontinuation (D/C) & flare protection post-D/C is associated with renal response, low disease activity & HCQ use at GC D/C. Membranous LN & recent diagnosis were assoc w early GC D/C @RheumNow https://t.co/agFgyG5eaS
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Should we still be worried about lymphoma developing in RA patients?
Incidence has plummeted with modern therapy, although still a small risk. TNFi and other bDMARDs don’t seem to confer any real risk.
So what should our approach be?
Karin Hellgren #EULAR2025 @RheumNow https://t.co/9ZodpojSaz
David Liew drdavidliew ( View Tweet)
About #Multidisciplinarity ...
Dr Ihsane Hmamouchi talking about Multidisciplinary Approach to Migrant #Rheumatology Care
#quotes
#EULAR2025
#Invitedspeaker
#outofthebox
@RheumNow
@epirheum https://t.co/RG6xpHejv9
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2025 Abstr#POS0991 RCT showed Adjuvanted Herpes Zoster vaccination appeared safe in #SLE upto 1 year. However, humoral and cellular responses declined over time. Longer follow up needed to ascertain frequency of vaccine to be repeated @RheumNow https://t.co/FcUi1OfBLu
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What kills in GCA?
Greek national prospective cohort, small numbers and no doubt some channeling bias, but:
Steroids (absence of DMARD use) is more of a factor than CV disease in GCA mortality.
With new options, all GCA pts should be on something
#EULAR2025 POS0960 @RheumNow https://t.co/Wmvf6tEvaF
David Liew drdavidliew ( View Tweet)
In PsA, can we better pick IL-17A inhibitor responders (after TNFi failure)?
Transcriptomic profiling is going to get better at telling us which pathways are truly important for response to specific treatments
POS0232 #EULAR2025 @RheumNow https://t.co/uycuXB0TFK
David Liew drdavidliew ( View Tweet)
KORAIL cohort
Prediction model for progression of RA-ILD at 3 years
A combination of classic clinical parameters incl DA , ILD pattern, ACPA KL-6 with AUC 0.75
HR=34 for progression in High risk group
Need validation in an external cohort
@RheumNow #EULAR2025 OP0329 https://t.co/LIvn1JCXPq
Aurelie Najm AurelieRheumo ( View Tweet)
#digital #ulcers in #scleroderma🎯
Retrospective #iloprost vs #selexipag
👇
BIG advantage of oral #prostacyclin receptor #agonist vs iloprost
healing faster
⬇️ulcers
Selexipag used in iloprost failures; ⬇️IV access
WOW! RCT needed #OP035
#EULAR2025 @RheumNow @eular_org https://t.co/6y9LwIlQkd
Links:
Janet Pope Janetbirdope ( View Tweet)
SLE Preview: advances to achieve deep B-cell depletion
The race is on for the first chimeric antigen receptor (CAR)-based therapy to be approved for the treatment of systemic lupus erythematosus (SLE). Its main principle is to induce deep B-cell depletion, with the hope to reset https://t.co/OzQ05YFZfb
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty
Dr. John Cush RheumNow ( View Tweet)
Diagnostic delay in #SpA
🔹️Data from the @Official_ASAS
Study
🔹️4339 patients
🔹️Delay was 6.6 years
🔹️Longer in axSpA and IBD-SpA, shorter in PsA and pSpA
🔹️Associated with type of initial symptoms (shorter in peripheral)
POS0909 #EULAR2025
@rheumnow https://t.co/3BMYFxbKiq
Nelly ZIADE 🍀 Nellziade ( View Tweet)
